GLP-1 Pills vs Injections: How Do They Compare?

For years, a GLP-1 weight-loss prescription meant learning to use an injection pen. That changed in December 2025, when the FDA approved the Wegovy pill, and again in April 2026, when it approved Foundayo (orforglipron). Now one of the most common questions people bring to a weight-loss visit is simple: should I take a pill or a shot?

The honest answer is that both work, they work in the same basic way, and the differences are mostly about strength, routine and practical details. This guide compares the GLP-1 pills and weekly injections approved for weight management in the US, using what their FDA labels and main trials actually show, so you can have a better-informed conversation with your clinician.

Educational only. This is not medical advice and not a recommendation for any product. Whether a weight-loss medicine is right for you, and in which form, is a decision to make with a licensed clinician who knows your full health history and medication list.

The short answer

GLP-1 pills and injections are both effective for weight loss, but in their main trials the weekly injections produced somewhat more average weight loss. Pills spare you needles and refrigeration but must be taken every day, and one of them, the Wegovy pill, comes with a strict morning routine. Side effects are mostly digestive and broadly similar across forms. For most people, the deciding factors are how much weight loss they and their clinician are aiming for, which routine they can stick with, what other medicines they take, and what they can afford.

The options being compared

As of October 2026, these are the main GLP-1-based products approved by the FDA for chronic weight management in adults that come up in the pill-versus-shot question:

Product	Active ingredient	Form	How often	FDA-approved for weight management?
Wegovy pill	Semaglutide	Tablet	Once daily	Yes, since December 22, 2025
Foundayo	Orforglipron	Tablet	Once daily	Yes, since April 1, 2026
Wegovy injection (including Wegovy HD 7.2 mg)	Semaglutide	Injection under the skin	Once weekly	Yes
Zepbound	Tirzepatide	Injection under the skin	Once weekly	Yes

Older daily injections such as liraglutide are also approved but are used less often today; our FDA-approved GLP-1s guide lists every option. If you are new to this class of medicines, start with what a GLP-1 medication is.

One important point before comparing: Zepbound is not a pure GLP-1 drug. Tirzepatide activates both the GLP-1 receptor and the GIP receptor, which is part of why it tends to produce more weight loss. There is currently no tirzepatide pill, so “pill vs injection” is partly a comparison of different molecules, not just different delivery methods.

How pills and injections get the medicine into your body

All of these medicines end up doing the same job: activating GLP-1 receptors in the brain and gut, which reduces appetite, increases fullness and slows stomach emptying. For the details, see how GLP-1s work for weight loss. The difference is the route.

Injections: the medicine goes straight under the skin

A weekly injection delivers the drug into the fatty tissue under the skin, where it is absorbed steadily into the blood. The Wegovy label puts the absolute bioavailability of injected semaglutide at about 89%, meaning nearly all of the dose reaches the bloodstream. Semaglutide’s half-life is about one week, which is why a single weekly dose is enough.

The Wegovy pill: a peptide that needs a bodyguard

Semaglutide is a peptide, a small protein, and the stomach is built to digest proteins. The Wegovy pill solves this with an absorption enhancer called SNAC, which protects the drug and helps it cross the stomach lining. Even so, the label says only about 1% to 2% of each tablet’s semaglutide is absorbed. That is why the pill’s maintenance dose is 25 mg every day, while the injection’s standard dose is 2.4 mg once a week.

The label states that in people without type 2 diabetes, average semaglutide blood levels are similar with the 25 mg daily pill and the 2.4 mg weekly injection, but they vary more from person to person with the pill. In the label’s figures, 90% of people on the pill had average levels between 27 and 186 nmol/L, compared with 51 to 110 nmol/L on the injection. We explain the absorption science in depth in oral semaglutide explained.

Foundayo: a small molecule that absorbs on its own

Orforglipron, the drug in Foundayo, is not a peptide at all. It is a small-molecule, non-peptide GLP-1 receptor agonist, closer to a conventional pill. Its label reports an average absolute bioavailability of 77% after a 0.8 mg dose and says there was no clinically relevant effect of food on how much of the drug is absorbed. Its half-life is about 29 to 49 hours, shorter than semaglutide’s, which is one reason it is taken daily. For the full story on this pill, see orforglipron (Foundayo) explained.

Weight loss: what the FDA labels show

Here are the headline results from the main placebo-controlled trials in each product’s FDA label, all in adults with obesity, or overweight plus a weight-related condition, without type 2 diabetes. Everyone also received diet and activity counseling.

Product and dose	Trial length	Average weight change on drug	Average change on placebo
Foundayo 17.2 mg daily (top dose)	72 weeks	-11.1%	-2.1%
Wegovy pill 25 mg daily	64 weeks	-13.6%	-2.4%
Wegovy injection 2.4 mg weekly	68 weeks	-14.9%	-2.4%
Wegovy injection 7.2 mg weekly	72 weeks	-18.8%	-3.9%
Zepbound 15 mg weekly (top dose)	72 weeks	-20.9%	-3.1%

Lower doses produced less. In Foundayo’s main trial, the 5.5 mg and 9 mg doses averaged -7.4% and -8.3%. In Zepbound’s, the 5 mg and 10 mg doses averaged -15.0% and -19.5%.

How to read these numbers fairly

• These were separate trials, not head-to-head comparisons. They enrolled different people, ran for different lengths and had different placebo results. The labels compare each drug with placebo, not with each other.
• The numbers include people who stopped treatment. The label figures count everyone who was randomly assigned. Companies often also publish a higher “if everyone kept taking it” number. For example, Lilly’s approval announcement highlights 12.4% for top-dose Foundayo among people who stayed on treatment, alongside 11.1% for everyone regardless of completion. Novo Nordisk highlighted 16.6% for the Wegovy pill on the same kind of basis. Both kinds of numbers are legitimate; they answer different questions.
• The Foundayo trial used an investigational formulation. The New England Journal of Medicine paper on ATTAIN-1 reports doses of 6, 12 and 36 mg; the label presents the same results as the equivalent marketed doses of 5.5, 9 and 17.2 mg.
• Averages hide a wide range. On top-dose Foundayo, 54.5% of people lost at least 10% of their body weight and 18.4% lost at least 20%, according to the label. Some people lose far more than average and some far less, on any of these medicines.

Yale Medicine summed up the picture in an April 2026 explainer: the pill and the injection “produce similar results, though the injection has a modest edge in clinical trial data.” Dr. Avlin Imaeda, a Yale Medicine gastroenterologist who is board-certified in obesity medicine, also noted that Foundayo targets one hormone receptor, unlike tirzepatide, which targets two, which may help explain why it produced somewhat less weight loss.

If you have type 2 diabetes

The picture shifts for people with diabetes, who tend to lose less weight on any GLP-1 medicine. In Foundayo’s trial in adults with type 2 diabetes, the top dose averaged -9.6% versus -2.5% on placebo. In Zepbound’s, the 15 mg dose averaged -14.7% versus -3.2%.

The Wegovy pill has a specific caution here. Its label says people with type 2 diabetes reach lower average semaglutide levels on the tablet than on the injection, that some may have levels too low to work well, and that clinicians should consider alternatives, including switching to the injection, if someone with diabetes does not respond adequately. If you have diabetes, this is an important point to raise with your prescriber.

Side effects: more alike than different

Because they act on the same receptor, pills and injections share the same main side effects: nausea, diarrhea, vomiting, constipation, indigestion and abdominal pain, usually worst when starting or increasing a dose.

A few numbers from the labels:

• Foundayo: digestive side effects affected 60% to 69% of people across doses, versus 37% on placebo. Nausea affected 26% to 35%, versus 10% on placebo. Overall, 8% stopped treatment because of side effects, versus 3% on placebo.
• Wegovy pill: 6.9% stopped because of side effects, versus 5.9% on placebo; digestive effects were the most common reason. Severe digestive reactions were reported in 2% on the tablet versus 0% on placebo. The label says the common side effects with the tablet were similar to those with the injection.
• Zepbound: nausea affected 25% to 29% of people, versus 8% on placebo.

Dr. Imaeda told Yale Medicine that side effects with the pills are “really pretty similar” to the shots and “no worse than with the shots.”

The one side effect that is unique to injections is injection-site reactions, such as redness or itching. In the Zepbound label they affected 6% to 8% of people versus 2% on placebo; in the Wegovy label, 1.4% versus 1%.

Pills and injections also share the same kinds of serious warnings, including a boxed warning about thyroid C-cell tumors seen in rodents, and warnings about pancreatitis, gallbladder problems, kidney injury from dehydration and a risk of food being inhaled into the lungs during anesthesia. Foundayo’s boxed warning is worded a little differently, because orforglipron is not active in rats or mice, but it still carries the same contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN 2. For practical tips on the most common problem, see GLP-1 nausea and our guide to managing side effects.

The daily routine: where pills and shots really differ

This is where the choice often gets made.

	Wegovy pill	Foundayo	Weekly injection
How often	Every morning	Once a day, any time	Once a week, same day each week
Food and drink	Empty stomach, up to 4 oz of plain water, then wait 30 minutes before food, drinks or other oral medicines	With or without food	No food rules
Missed dose (per label)	Skip it and take the next one the following day	Take it as soon as possible; do not double up; after 7 or more missed days, restart at a lower dose	Wegovy: take it if the next dose is more than 2 days away. Zepbound: take it within 4 days, otherwise skip
Storage	Room temperature, original bottle	Room temperature	Refrigerator, with limited time allowed at room temperature
Needles	None	None	Yes

The Wegovy pill’s morning rules

The Wegovy pill’s label asks you to take it first thing in the morning on an empty stomach, with no more than 4 ounces of plain water, swallowed whole, and then to wait at least 30 minutes before eating, drinking anything else or taking other oral medicines. These rules exist because food and extra liquid reduce how much semaglutide gets absorbed. They can be easy for some people and hard for others, especially people who take other morning medicines that have their own empty-stomach rules, such as thyroid medicine. The label reports that levothyroxine exposure rose by 33% in a study when it was taken with the semaglutide tablet.

Foundayo’s flexibility, and its own interactions

Foundayo can be taken at any time of day, with or without food. That flexibility is its main practical advantage. It has a different set of label rules, though:

• Some medicines that strongly block a liver enzyme called CYP3A4 limit Foundayo to a maximum of 9 mg a day, and some others should be avoided.
• People taking simvastatin, a cholesterol drug, should not take more than 20 mg a day of it alongside Foundayo.
• People using birth control pills are advised to switch to a non-oral method, or add a barrier method, for 30 days after starting Foundayo and after each dose increase.

Zepbound’s label has a similar birth control instruction, for 4 weeks after starting and after each dose increase. Because every GLP-1 medicine slows stomach emptying, all of them can affect how other pills are absorbed. Give your prescriber and pharmacist a complete list of everything you take, including supplements.

Weekly injections: one dose, but a needle

Weekly injections involve the least day-to-day effort: one dose, on the same day each week, at any time, with no food rules. The trade-offs are needles, refrigerator storage and, for some products, extra steps. Zepbound now comes as single-dose pens, single-dose vials, multi-dose vials and a multi-dose KwikPen, and the Wegovy label includes a multi-dose FlexTouch pen. Both labels warn that multi-dose pens must never be shared, even with a new needle. Our tirzepatide hub covers the pen and vial options.

Storage and travel

GLP-1 pills are stored at room temperature, between 68°F and 77°F, and the Wegovy pill must stay in its original bottle to protect it from moisture. Injections are kept in the refrigerator before use, with label limits on time out of the fridge: up to 28 days for Wegovy single-dose pens, up to 21 days for Zepbound single-dose pens and vials, and 30 days at room temperature for Zepbound multi-dose vials and KwikPens. FDA also advises not to use any injectable GLP-1 that arrives warm.

Needles, preferences and what people actually choose

Fear of needles is common. A 2019 systematic review in the Journal of Advanced Nursing found needle-fear estimates of 20% to 30% among young adults, decreasing with age, and that 16% of adult patients in the studies reviewed avoided a flu shot because of it.

But needle fear is not the whole story, and research on preferences is more nuanced than “everyone wants a pill”:

• In the REVISE survey of 600 adults with type 2 diabetes in the US and UK, 76.5% initially said they preferred a daily pill over a weekly injection. After watching videos showing how each product is actually used, including the oral semaglutide routine, preferences split almost evenly: 52.5% for the pill and 47.5% for the weekly injection. The most common reason people changed their minds was the timing and steps involved.
• In an Australian study of adults with overweight or obesity, most patients reported relatively low needle fear, while physicians believed their patients’ needle fear was higher. The authors suggested that people may be less worried about injectable weight-loss medicines than doctors assume.
• In OPTIC, a 2026 online survey of 800 US adults with overweight or obesity, the way a medicine is taken was one of the most important factors in people’s choices, along with average weight loss and heart-risk reduction. Only 23.4% said taking a medicine on an empty stomach and waiting 30 minutes to eat would be disruptive. The poster for this study is hosted on the website of Novo Nordisk, which makes the Wegovy pill, and the survey used hypothetical choices, so read it with both points in mind.

The takeaway: preferences are personal and can change once people understand the real routine. Neither form is “better” for everyone.

Cost and coverage

Prices change often, but in October 2026 the manufacturers’ own self-pay listings showed pills at the lower end. Novo Nordisk’s NovoCare Pharmacy listed the Wegovy pill at $149 a month for the 1.5 mg dose, $199 for 4 mg and $299 for the 9 mg and 25 mg doses. It listed the Wegovy injection at $199 a month for the first two fills of the starting doses for new patients, through December 31, 2026, then $349 a month, with Wegovy HD 7.2 mg at $399. Lilly said in its approval announcement that Foundayo self-pay starts at $149 a month for the lowest dose. Lilly also offers self-pay pricing for Zepbound, which varies by dose and form.

Yale Medicine notes that out-of-pocket costs for the pills are “generally lower than injections,” but that coverage varies widely by plan. Insurance rules, savings cards and Medicare’s temporary GLP-1 Bridge program each have their own conditions. See does insurance cover GLP-1s for weight loss?, semaglutide cost without insurance and our GLP-1 cost guide before you decide.

A safety note on price: FDA warns about unapproved and counterfeit GLP-1 products sold online, and compounded versions are not FDA-approved. A compounded or unapproved “GLP-1 pill” is not the same as the Wegovy pill or Foundayo, and their trial results do not apply to it.

GLP-1 patches vs shots: is there a GLP-1 patch?

No FDA-approved GLP-1 patch exists. FDA told TODAY.com plainly: “There are no FDA-approved GLP-1 patches.” Every approved GLP-1 medicine is either an injection or a tablet.

The “GLP-1 patches” sold online are usually supplement-style products. They typically list ingredients such as berberine, green tea extract, cinnamon or vitamins, not semaglutide or tirzepatide. Cleveland Clinic explains why they cannot work like the real drugs: GLP-1 medicines are large molecules that do not pass through the skin easily, which is why the approved ones come as shots or pills. There is also no evidence that berberine is absorbed through the skin. And because these products are not FDA-approved, there is no reliable way to know what is in them, and some may contain unlisted ingredients.

How they compare with a weekly shot:

	FDA-approved GLP-1 injection or pill	“GLP-1 patch” sold online
Contains a GLP-1 drug	Yes	No, in the products described by clinicians and FDA
FDA-reviewed for safety and effectiveness	Yes	No
Human trial evidence for weight loss	Yes, large placebo-controlled trials	None
Needs a prescription	Yes	No

A useful rule of thumb from pharmacologists: if you can buy it without a prescription, it is not an actual GLP-1 drug. Researchers are working on microneedle and transdermal GLP-1 delivery, but those are still experimental. If needles are the barrier, the approved alternative is a pill: the Wegovy pill or Foundayo, as compared above.

Common myths, corrected

“Pills are a weaker version of the shot.” Partly true, partly not. The Wegovy pill is the same drug, and its average blood levels and trial weight loss come close to the 2.4 mg injection in people without diabetes. Foundayo is a different molecule and produced less average weight loss in its trials than the leading injections.

“Pills don’t cause stomach side effects.” They do. Digestive side effects were common with both pills in their trials, at rates broadly similar to injections.

“Pills have no serious risks because there’s no needle.” The serious warnings in the labels, including pancreatitis, gallbladder disease and the thyroid tumor boxed warning, apply to the pills as well.

“You can take a pill and a shot together for extra effect.” No. The labels say using two GLP-1 receptor agonists together is not recommended.

“Any morning pill routine works for the Wegovy pill.” Not if it includes coffee, a large glass of water or other medicines in the first 30 minutes. Those can reduce absorption.

How to decide, with your clinician

There is no universal winner. These questions can help you and your clinician narrow it down:

1. What is my goal? If the aim is the largest average weight loss, the leading weekly injections had the strongest trial results. If a pill is the only option you would actually start, a pill that you take consistently is likely to help more than an injection you avoid.
2. Which routine fits my life? A strict 30-minute morning routine every day, a flexible daily pill, or one injection a week?
3. What else do I take? Thyroid medicine, birth control pills, statins, some HIV medicines and other drugs can change which option makes sense.
4. Do I have type 2 diabetes? It affects expected weight loss and, for the Wegovy pill, absorption.
5. How do I feel about needles, refrigeration and travel?
6. What will it cost me, month after month, including higher maintenance doses?

“The choice between a pill and an injection comes down to individual priorities and how easily the treatment fits into their life,” Dr. John Morton, chief of bariatric and minimally invasive surgery at Yale Medicine, told Yale Medicine. Yale’s specialists also note that if you are already on an injection that is working well, there may be no reason to switch.

To get started, see how to get a GLP-1 prescription and who qualifies for GLP-1 weight-loss treatment. For brand comparisons within each form, see Wegovy vs Ozempic, Zepbound vs Mounjaro and our semaglutide vs tirzepatide guide.

What people are saying online

On X, recent posts about GLP-1 pills mostly celebrate “no needle, no fridge,” debate whether pills will replace shots, and compare weight-loss percentages from different labels side by side, sometimes mixing “everyone randomized” numbers with “everyone who stayed on the drug” numbers. On YouTube, weight-medicine doctors have posted many pill-versus-shot explainers, and most land in the same place as the labels: the injections have an edge in average weight loss, while pills can be the better fit for people who would otherwise not start treatment. Social posts and videos can help you think of questions, but they are not medical evidence, and they cannot account for your health history.

The bottom line

GLP-1 pills and injections use the same biology to reduce appetite and support weight loss. In their FDA-label trials, weekly injections, especially Zepbound and higher-dose Wegovy, produced more average weight loss than the pills, while the Wegovy pill came close to the standard Wegovy injection in people without diabetes. Pills avoid needles and refrigeration but must be taken daily, and the Wegovy pill requires a strict morning routine; Foundayo is more flexible but has its own drug interactions. Side effects and serious warnings are broadly similar. The best option is the one that fits your goals, health, other medicines and budget, and that you can take consistently, chosen together with a licensed clinician.

Explore more in the Oral & New GLP-1s hub, the Semaglutide hub and the GLP-1 Guide hub.